IV Abatacept — Competitive Intelligence Brief

IV Abatacept (IV Abatacept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell costimulation inhibitor. Area: Immunology.

marketed T-cell costimulation inhibitor CD80/CD86 Immunology Small molecule

Target snapshot

IV Abatacept (IV Abatacept) — Rüdiger B. Müller. Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV Abatacept TARGET	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
ABT	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
Open-label Abatacept	Open-label Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell costimulation inhibitor)	CD80/CD86
Abatacept subcutaneous	Abatacept subcutaneous	Bristol-Myers Squibb	phase 3	T-cell co-stimulation modulator	CD80/CD86
Subcutaneous (SC) abatacept	Subcutaneous (SC) abatacept	Bristol-Myers Squibb	phase 3	T-cell costimulation modulator	CD80/CD86

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell costimulation inhibitor class)

1. Bristol-Myers Squibb · 1 drug in this class
2. Rüdiger B. Müller · 1 drug in this class
3. University Hospital, Montpellier · 1 drug in this class
4. University of Minnesota · 1 drug in this class